<DOC>
	<DOC>NCT00421122</DOC>
	<brief_summary>This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug Administration.</brief_summary>
	<brief_title>Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Signed and dated inform consent Outpatient, clinical diagnosis of COPD Men or women at the age of 40 or over A history of asthma Seasonal allergic rhinitis before 40 years of age Patients with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator or other disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Chinese patients</keyword>
	<keyword>COPD</keyword>
</DOC>